Physician profile
William Lyman
NPI 1760003321
$7,654.38
in general payments reported to CMS, 2019-2025
26 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,584 · 2022: $1,136 · 2023: $1,122 · 2024: $2,084 · 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,922 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,922.22 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,034.28 | 2021-2025 | |
| Corium, LLC | $585.86 | 2023-2025 | Azstarys, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $581.88 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $486.65 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $482.51 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $467.62 | 2021-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $459.69 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Lundbeck LLC | $336.58 | 2021-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $282.25 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $194.71 | 2024-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Tris Pharma INC | $194.29 | 2022-2025 | Dyanavel Xr |
| Indivior INC. | $171.21 | 2021-2025 | Sublocade, Perseris |
| Idorsia Pharmaceuticals US INC | $165.86 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $155.47 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $153.53 | 2021-2025 | Loreev Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $143.99 | 2021-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $117.84 | 2021-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $113.05 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $103.37 | 2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $102.62 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $87.38 | 2021 | |
| Biogen, INC. | $73.74 | 2025 | Skyclarys, Zurzuvae |
| Eisai INC. | $66.25 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $63.91 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $15.78 | 2025 | Relexxii |
| Orexo US, INC. | $14.06 | 2023 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.